Shattuck Labs, Inc. (STTK) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Shattuck Labs, Inc. (STTK) closed at USD 5.33 on 2026-10-14, a change of +166.5 % over the past year, with a market capitalization of USD 555.01M.

Shattuck Labs, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Shattuck Labs, Inc. key figures

Previous close

USD 5.33 (2026-10-14)

1-year change

+166.5 %

Market cap

USD 555.01M

Enterprise value

USD 349.38M

P/E ratio (trailing)

-11.52

P/E ratio (forward)

-10.70

EPS (trailing)

-0.48

EPS (forward)

-0.52

PEG ratio

n/a

Price to book

2.64

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.22

Employees

40

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Shattuck Labs, Inc.

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Shattuck Labs, Inc. and compare it with other stocks.